Comparability Protocols Should Specify Tests And Expected Results - CBER
Executive Summary
Failure to outline specific tests and anticipated results is the major reason comparability protocols are rejected, FDA Office of Therapeutics Research & Review Deputy Director Sharon Risso told the Food & Drug Law Institute July 14 in Washington, D.C.